Medical management of frontotemporal dementia

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.

Original languageEnglish (US)
Pages (from-to)489-498
Number of pages10
JournalAmerican Journal of Alzheimer's Disease and other Dementias
Volume22
Issue number6
DOIs
StatePublished - Jan 2008

Fingerprint

Frontotemporal Dementia
Motor Neuron Disease
Weapons
United States Food and Drug Administration
Primary Prevention
Secondary Prevention
Psychotic Disorders
Caregivers
Psychiatry
Life Style
Alzheimer Disease
Anxiety
Depression
Drug Therapy
Sleep Wake Disorders

Keywords

  • Dementia and motor neuron disease
  • Frontotemporal dementia
  • Pharmacotherapy of dementia

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Medical management of frontotemporal dementia. / Caselli, Richard John; Yaari, Roy.

In: American Journal of Alzheimer's Disease and other Dementias, Vol. 22, No. 6, 01.2008, p. 489-498.

Research output: Contribution to journalArticle

@article{2047fff596e14e1aac248b9699c01e2a,
title = "Medical management of frontotemporal dementia",
abstract = "There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.",
keywords = "Dementia and motor neuron disease, Frontotemporal dementia, Pharmacotherapy of dementia",
author = "Caselli, {Richard John} and Roy Yaari",
year = "2008",
month = "1",
doi = "10.1177/1533317507306654",
language = "English (US)",
volume = "22",
pages = "489--498",
journal = "American Journal of Alzheimer's Disease and other Dementias",
issn = "1533-3175",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Medical management of frontotemporal dementia

AU - Caselli, Richard John

AU - Yaari, Roy

PY - 2008/1

Y1 - 2008/1

N2 - There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.

AB - There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.

KW - Dementia and motor neuron disease

KW - Frontotemporal dementia

KW - Pharmacotherapy of dementia

UR - http://www.scopus.com/inward/record.url?scp=38749125564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749125564&partnerID=8YFLogxK

U2 - 10.1177/1533317507306654

DO - 10.1177/1533317507306654

M3 - Article

C2 - 18166608

AN - SCOPUS:38749125564

VL - 22

SP - 489

EP - 498

JO - American Journal of Alzheimer's Disease and other Dementias

JF - American Journal of Alzheimer's Disease and other Dementias

SN - 1533-3175

IS - 6

ER -